Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, do
Authors
Y. Tong (ORCID: https://orcid.org/0009-0002-6444-4471)
Xiran He
Changwen Ke (ORCID: https://orcid.org/0000-0003-2702-8823)
Zhaohong Li (ORCID: https://orcid.org/0000-0001-6463-7666)
Zhonghua Yang (ORCID: https://orcid.org/0000-0001-8341-4775)
Ministry of Science and Technology of the People's Republic of China
National Science and Technology Major Project
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, do
Y. Tong, Xiran He, Changwen Ke, Zhaohong Li et al.
Citations
1 citations
Journal
Expert Review of Vaccines
Topics
SARS-CoV-2 and COVID-19 Research
Field-Weighted Citation Impact (FWCI)
0.39
article
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, do
Hubei Provincial Center for Disease Control and Prevention (CN), People's Hospital of Shiyan (CN), Taiwan Centers for Disease Control (TW)
Funders
Health Commission of Hubei Province, Ministry of Science and Technology of the People's Republic of China, National Science and Technology Major Project